Research programme: immune modulation therapy - Lorantis

Drug Profile

Research programme: immune modulation therapy - Lorantis

Alternative Names: LOR-A04; LOR-S01; LOR-S03

Latest Information Update: 07 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lorantis
  • Developer Celldex Therapeutics Inc; Lorantis
  • Class DNA; Proteins
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Allergic asthma; Cancer; Immunological disorders; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection; Viral infections

Most Recent Events

  • 12 Oct 2005 Lorantis has been acquired by Celldex Therapeutics
  • 23 Mar 2004 Preclinical trials in Cancer in United Kingdom (unspecified route)
  • 23 Mar 2004 Preclinical trials in Viral infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top